Want to contact a Zelnorm attorney in Washington, DC?...Get a free case evaluation from one of our Zelnorm attorneys in Washington, DC now.
Home : Unsafe Drugs : Zelnorm : MSN Newsfeeds
Zelnorm - MSN Newsfeeds
- Forbes - However, with the recent product suspension of Zelnorm, used to treat irritable bowel syndrome, and early generic erosion of Lotrel, a hypertension treatment, Lamasil, an anti-fungus treatment, and Famvir, an anti-virus medication, sales growth will ...
- Bloomberg - Cheap copies cut into sales of Trileptal for epilepsy and the Lotrel hypertension drug. Two other products were also hurt by generics, and Novartis lost sales from the recall of the Zelnorm irritable bowel treatment. Revenue rose at the ...
- Street.Com - ... ahead, the company said results of its pharmaceuticals division will be negatively affected in the first two quarters of 2008 by the full-year effect of having lost significant sales contributions from five products -- Zelnorm, Lotrel, Trileptal ...
- CNBC - The withdrawal of its bowel drug Zelnorm from the U.S. market and generic competition for some of its best-selling products, including hypertension drug Lotrel, squeezed results. "The weak performance is exclusively due to the U.S. market," Novartis ...
- International Herald Tribune - The company took major hits from delays in approval of key diabetes drug Galvus and the withdrawal of bowel treatment Zelnorm in the United States. In response, it cut 2.5 percent of its workforce, aiming for annual savings of $1.6 billion in 2010. It ...
- Reuters - Novartis suffered a series of setbacks in 2007, including delays to important drugs like Galvus for diabetes and the withdrawal of bowel treatment Zelnorm in the United States. It cut 2.5 percent of its workforce, aiming for annual savings of $1.6 ...
- Earthtimes - ... rise 11% (+6% in local currencies) to USD 38.1 billion on strong contributions particularly from Sandoz and Vaccines and Diagnostics * Pharmaceuticals in the US adversely impacted by generic competition and Zelnorm ...
- Phramalive.com - Zelnorm(R) (tegaserod, Novartis) was the only approved drug for IBS with constipation (IBS-c) and was suspended from marketing by the FDA in March 2007, except in rare and restrictive cases. Lotronex(R) (alosetron, GSK) is the only drug approved by ...
- BusinessWeek - In addition, safety concerns hurt some European Union pharma megaproducts already on the market, including GSK's Avandia (diabetes) and Novartis' Zelnorm (gastrointestinal), increasing the urgency for new products. Analysts believe that in 2008, Food ...
- WCAX - Until recently, Zelnorm, a drug made by Novartis Pharmaceuticals, had been approved for treating both groups of patients. But on March 30, the company pulled it from the market after new data indicated an increased risk of heart attack, stroke and ...
- Newark Star-Ledger - In addition, lost sales to generic competition and the market withdrawal of the irritable bowel drug Zelnorm amounted to $1.5 billion this year, with a similar impact expected next year, the company said. Some 1,760 of the new round of job losses ...
- MSNBC - Growth in the U.S. will be hurt by the loss of sales from bowel drug Zelnorm and generic competition for the company's Lamisil, Lotrel, Famvir and Trileptal drugs, the company said. "We expect the first quarter to again be strongly negative, while ...
- Wall Street Journal - Earlier this year, it also was forced to withdraw from the U.S. and Swiss markets its drug for irritable-bowel syndrome, Zelnorm, after safety concerns. "Now that we had quite a difficult year, a challenging year after so many years of gaining market ...
- Bloomberg - Zelnorm, a bowel drug, was pulled from the U.S. market. In September, U.S. regulators denied Novartis permission to sell its Prexige pain drug. Novartis bought seven pharmaceutical companies in the last two years, including vaccine maker ...
- KMOV - Since Zelnorm, a popular drug marketed to thousands of women for IBS, was recently removed from the market, Dr. Schiller said many patients find relief with the bifidobacterium probiotic. While experts say buyers should beware ...
- Forbes - ... drug that either blocked or enhanced the ability of the ligand to connect with its receptor. Eli Lilly (nyse: LLY - news - people )'s Zyprexa, Glaxo's Zantac and Novartis (nyse: NVS - news - people )' Zelnorm are all ...
- Motley Fool - The slow growth was a result of the continued impact of the sales halt on Zelnorm in the U.S. and multiple generic launches on top drugs like Lamasil. Backing out one-time charges and discontinued operations, Novartis' operating income was up 3 ...
- Wall Street Journal - Sales of irritable-bowel-syndrome drug Zelnorm have plummeted 80% this year after the company withdrew the drug from the market in March at the request of the FDA, which was concerned about a possible link to angina, heart attacks and strokes ...
- Newark Star-Ledger - Delays in Food and Drug Administration approval of the diabetes drug Galvus and the painkiller Prexige, coupled with the market withdrawal of the irritable-bowel treatment Zelnorm, all contributed to disappointing sales. So did generic competition to ...
- Bloomberg - Novartis needs to control costs after sales were hurt by the withdrawal of Zelnorm and the start of generic competition to heart medicine Lotrel, genital herpes treatment Famvir and anti- fungal Lamisil. In September, the company failed to win U.S ...
Want to contact a Zelnorm attorney in Washington, DC?...Get a free case evaluation from one of our Zelnorm attorneys in Washington, DC now.
Pages: 1 2 3 4 5 6 Next
